Articles Published in 2013

Merck to cut another 8,500 jobs, sharpen pipeline, shutter facilities

Wednesday, October 2, 2013 12:37 PM

In a move to create greater efficiencies, Merck announced the elimination of another 8,500 positions, in addition to previously reported reductions of 7,500 jobs, with a goal of paring annual operating expenses by approximately $2.5 billion by the end of 2015.

More... »

inVentive Health names president for Europe and executive VP for Asia

Tuesday, October 1, 2013 12:00 PM

Global CRO inVentiv Health has created two new positions to lead its business in Europe and Asia.

More... »

Olivier Brandicourt appointed chairman of Bayer HealthCare

Tuesday, October 1, 2013 11:00 AM

Olivier Brandicourt has been appointed chairman of the board of management of Bayer HealthCare and member of the Bayer executive council effective Nov. 1. Since March, professor Wolfgang Plischke has led Bayer HealthCare on an interim basis in addition to his existing duties as a Bayer board member.

More... »

Merck to continue development of Tecemotide in phase III trial

Tuesday, October 1, 2013 10:30 AM

Merck Serono, the biopharmaceutical division of Merck, has decided to continue clinical development of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide  (also known as L-BLP25 and formerly known as Stimuvax). Merck Serono, which is developing tecemotide under a license agreement with Oncothyreon, will conduct a new phase III trial called START2 for patients with unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).

More... »

Caris Life Sciences study reports positive results for evidence-guided tumor profiling

Tuesday, October 1, 2013 10:00 AM

Caris Life Sciences, a biosciences company focused on personalized medicine, has announced data from two studies which demonstrate the potential of evidence-guided tumor profiling to immediately improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) and rarer and refractory cancers.

More... »

Theorem Clinical Research names Joseph Sgherza head of infectious diseases

Tuesday, October 1, 2013 09:44 AM

Global CRO Theorem Clinical Research has named Joseph Sgherza vice president of biopharmaceutical development for its infectious disease franchise. Sgherza has 24 years in the pharmaceutical, biotech and CRO industries.

More... »

The CenterWatch Monthly, October 2013

Tuesday, October 1, 2013 09:00 AM

New growth and decline in Asia clinical trials

More... »

Lundbeck simplifies and restructures, 200 jobs to be cut

Monday, September 30, 2013 03:40 PM

Lundbeck, a global pharmaceutical company specialized in brain diseases, has simplified its commercial structure, increased alignment across countries and improved competencies and investments in market access as a result of its Fit-for-the-Future program.

More... »

GlaxoSmithKline sells brands, plant to Aspen Group

Monday, September 30, 2013 02:50 PM

GlaxoSmithKline has reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine, and the Notre-Dame de Bondeville (NDB) manufacturing site to the Aspen Group, a South African pharmaceuticals company, for $1.13 billion in cash, of which $161.9 million relates to inventory. 

More... »

Life Technologies launches EZQC Online

Monday, September 30, 2013 02:46 PM

Life Technologies, a global biotechnology company, has launched EZQC Online, a web-based tool for quality control management in molecular diagnostic labs. EZQC Online contains three modules: a guidance tool for initial validation and verification of molecular tests, a tool to help labs meet CLIA standards for calibration verifications and a tool for ongoing quality control monitoring that provides an opportunity for peer-to-peer comparisons.

More... »